Finding Better Treatments for Bladder Cancer

We are pleased to report that we have submitted our application (BLA) to the FDA to approve N-803 + BCG for BCG-Unresponsive NMIBC CIS. If approved, this would be the first new immunotherapy for this indication in 23 years that can be delivered directly to the bladder to induce natural killer cells and T cells.

Learn More

 

Building for the Future

Are you mission-driven and interested in working in a fast-paced, collaborative environment? We’re hiring in our new state-of-the-art facility in Dunkirk, New York.

Learn More

 

Outsmart
Your Disease®

ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.

 

Our COVID-19 Research

Our researchers are developing COVID-19 vaccines that are designed to be more practical to make, store, and distribute than existing vaccines, with the potential to protect people from current and future SARS-CoV-2 variants and also be a boost to current COVID-19 vaccines.

Learn More

Solutions for Patients

Many therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.
Learn More

Opportunities for Trial Investigators

Immunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.
Learn More

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
Learn More
Dr. Patrick Soon-Shiong
Executive Chairman, ImmunityBio
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
 

Smart Therapies for Difficult Diseases®

Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.

Our Science
Our Approach
Our Science Our Approach

Investigational Cancer Therapies

ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by activating the natural killer cell, T cells, macrophages, and inducing memory through dendritic cells. Clinical trials orchestrating these unique therapies, which harness both the innate and adaptive immune system, are in progress across multiple tumor types.

Pancreatic Cancer Non-Small Cell Lung Cancer Triple-Negative Breast Cancer Bladder Cancer Glioblastoma

Investigational Viral Therapies

Infected cells, like cancer cells, can be exposed to enable recognition and killing by our natural killer cell and T cell platforms. Current clinical trials addressing HIV, COVID, and infectious diseases are in progress. The potential to administer these vaccines orally will enable greater global access.

HIV Covid-19
See All Research

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us

A Robust Clinical Pipeline

ImmunityBio's investigational immunotherapies are currently being studied for cancer and infectious disease in a range of clinical trials at various stages.

See Pipeline

Latest News & Events

Visit Newsroom